News coverage about Sinovac Biotech (NASDAQ:SVA) has trended somewhat positive on Tuesday, according to Accern Sentiment. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Sinovac Biotech earned a news impact score of 0.02 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 44.4772127951295 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Shares of Sinovac Biotech (SVA) opened at $7.99 on Tuesday. Sinovac Biotech has a fifty-two week low of $4.60 and a fifty-two week high of $8.11.
Separately, BidaskClub downgraded shares of Sinovac Biotech from a “strong-buy” rating to a “buy” rating in a report on Thursday, December 7th.
WARNING: “Sinovac Biotech (SVA) Earns Media Impact Score of 0.02” was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://sportsperspectives.com/2017/12/19/sinovac-biotech-sva-earns-media-impact-score-of-0-02.html.
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps.
Receive News & Ratings for Sinovac Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech and related companies with MarketBeat.com's FREE daily email newsletter.